By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genmab A/S 

Toldbodgade 33

Copenhagen    K-1253  Denmark
Phone: 45-7020-2728 Fax: 45-7020-2729


Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.


February 1999


CEO and Founder: Jan G. J. van de Winkel, Ph.D.

CFO: David Eatwell

Please click here for Genmab job opportunities.


Please click here for clinical trial information.


All Products


Key Statistics

Ownership: Public

Web Site: Genmab A/S
Symbol: GEN.CO



Bionomics Limited  Anti-angiogenesis therapeutic antibody development

Company News
Genmab A/S (GEN.CO) Announces European Marketing Authorization For DARZALEX (Daratumumab) For Relapsed Or Refractory Multiple Myeloma 4/28/2017 8:09:53 AM
Genmab A/S (GEN.CO) Announces New Phase III Combination Study Of Daratumumab In Multiple Myeloma 4/28/2017 8:08:31 AM
Genmab A/S (GEN.CO) Announces Net Sales Of DARZALEX (Daratumumab) For First Quarter Of 2017 4/18/2017 11:12:26 AM
Johnson & Johnson (JNJ) Stops Mid-Stage Trial For Genmab A/S (GEN.CO)'s Blood Cancer Drug Due To Futility 3/31/2017 5:51:26 AM
Grant Of Restricted Stock Units To Two New Board Members And Grant Of Restricted Stock Units And Warrants To The New Member Of Management In Genmab A/S (GEN.CO) 3/30/2017 11:26:36 AM
Constitution Of The Board Of Directors In Genmab A/S (GEN.CO) And Grant Of Restricted Stock Units And Warrants To Employees In Genmab 3/28/2017 11:22:26 AM
Genmab A/S (GEN.CO) 2016 Annual Report 2/23/2017 12:27:20 PM
Genmab A/S (GEN.CO) Appoints Judith Klimovsky, MD, As Chief Development Officer 2/8/2017 9:42:51 AM
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017 7:36:55 AM
Genmab A/S (GEN.CO) Achieves USD 25 Million Sales Milestone In DARZALEX (Daratumumab) Collaboration With Janssen Pharmaceutica N.V. 1/9/2017 7:29:42 AM